BioMarin Pharmaceutical Inc. announced last November that longtime CEO Jean-Jacques Bienaimé would retire, with Genentech, Inc. CEO Alexander Hardy replacing him, and changes to its C-suite have continued since then. The company said on 21 August that Amgen, Inc. vice president of medical affairs, rare diseases Greg Friberg will become EVP and chief research and development officer, effective 30 September, and Hardy’s former colleague, retired Roche Pharma Partnering head James Sabry, has been named EVP and chief business officer, effective 7 October.
BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team
Third And Fourth C-Suite Changes Since November
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
More from Leadership
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.